Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2086297 | 1.00 | SOS1 (0.31) | SOS1SOS2 | |
| SCHEMBL3390990 | 0.97 | — | — | |
| SCHEMBL22010942 | 0.97 | — | — | |
| SCHEMBL3390987 | 0.97 | — | — | |
| SCHEMBL19825217 | 0.90 | — | — | |
| SCHEMBL28693668 | 0.90 | — | — | |
| SCHEMBL13806584 | 0.88 | ALDH1A1 (0.36) | SOS1SOS2 | |
| Hydrochloric Acid SCHEMBL25189965 | 0.84 | — | — | |
| Hydrochloric Acid SCHEMBL7011180 | 0.84 | — | — | |
| SCHEMBL4515477 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102079743-B | Dipeptidyl peptidase inhibitors | 武田药品工业株式会社 | 2020-08-25 | — | — | CN | disclosed |
| CN-102134231-B | Dipeptidyl peptidase inhibitors | 武田药品工业株式会社 | 2020-08-04 | — | — | CN | disclosed |
| CN-102134229-B | Dipeptidyl peptidase inhibitors | 武田药品工业株式会社 | 2020-08-04 | — | — | CN | disclosed |
| US-8329900-B2 | Immunosuppressants; autoimmune disease; antiinflammatory agents; multiple sclerosis; rheumatic diseases; antiarthritic agents; aids; preparing, for example, 2-{6-[3-Amino-piperidin-1-yl]-3-ethyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl}-benzonitrile | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-11 | — | — | US | disclosed |
| US-8288539-B2 | Immunosuppressants; autoimmune disease; antiinflammatory agents; multiple sclerosis; rheumatic diseases; antiarthritic agents; aids; for example, 2-{6-[3-Amino-piperidin-1-yl]-3-ethyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl}-benzonitrile | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-16 | — | — | US | disclosed |
| CN-102675221-A | Intermediate in method for preparing pyrimidinedione derivative | TAKEDA PHARMACEUTICAL | 2012-09-19 | — | — | CN | disclosed |
| EP-1924567-B1 | PROCESS FOR THE PREPARATION OF PYRIMIDINEDIONE DERIVATIVES | TAKEDA PHARMACEUTICAL (JP) | 2012-08-22 | — | — | EP | disclosed |
| US-8222411-B2 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-07-17 | — | — | US | disclosed |
| US-8188275-B2 | hydrolase enzyme inhibors such as 2-(6-Chloro-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl)-benzonitrile | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-29 | — | — | US | disclosed |
| US-8173663-B2 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-08 | — | — | US | disclosed |
| US-20080161562-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | FENG JUN | 2008-07-03 | — | — | US | disclosed |
| EP-1924567-A2 | PROCESS FOR THE PREPARATION OF PYRIMIDINEDIONE DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2008-05-28 | — | — | EP | disclosed |
| US-20080108807-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | FENG JUN | 2008-05-08 | — | — | US | disclosed |
| US-20080108808-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | FENG JUN | 2008-05-08 | — | — | US | disclosed |
| US-20080003283-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY, INC. (JP) | 2008-01-03 | — | — | US | disclosed |
| WO-2007035629-A2 | PROCESS FOR THE PREPARATION OF PYRIMIDINEDIONE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-29 | — | — | WO | disclosed |
| CN-1926128-A | Dipeptidyl peptidase inhibitors | TAKEDA SAN DIEGO INC (JP) | 2007-03-07 | — | — | CN | disclosed |
| US-20050261271-A1 | Dipeptidyl peptidase inhibitors | TAKEDA SAN DIEGO, INC. | 2005-11-24 | — | — | US | disclosed |
| EP-1586571-A1 | Dipeptidyl peptidase inhibitors | Takeda San Diego, Inc. (US) | 2005-10-19 | — | — | EP | disclosed |
| WO-2005095381-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108807-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | DPP4, DPP3, DPP9 | SOS1 2289/4885SOS2 2848/4885 |
| US-20080003283-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | DPP4, DPP7, DPP3 | SOS1 4317/4885SOS2 4388/4885 |
| US-20080161562-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | DPP4, DPP3, DPP9 | SOS1 2289/4885SOS2 2848/4885 |
| US-20050261271-A1 | Dipeptidyl peptidase inhibitors | DPP4, DPP3, DPP9 | SOS1 2289/4885SOS2 2848/4885 |
| US-20080108808-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | DPP4, DPP3, DPP9 | SOS1 2289/4885SOS2 2848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.